AbbVie's migraine drug cleared for migraine attacks on NHS
AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
Newsletters and Deep Dive digital magazine
AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.
A PCR diagnostic developed by Roche for the Bundibugyo form of Ebola is being offered to health systems at the front lines of the current outbreak.
Clinical trials struggle in many areas, and significantly in recruitment.
AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.
Editor's Picks
Newsletters and Deep Dive
digital magazine